Navigation Links
Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented

SAN ANTONIO Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab.

"So far, no efficacy data from Phase III trials have been reported for early breast cancer. This will be the first," said von Minckwitz. "If the pathological complete response rate is higher with bevacizmab than without bevacizumab, it will provide a new option to improve neoadjuvant treatment in HER2-negative breast cancer."

Bevacizumab is currently approved in the United States in combination with paclitaxel for the first-line treatment of metastatic breast cancer. In July 2010, the Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12 to 1 to eliminate this indication from the treatment label of bevacizumab.

"A negative or positive result might have a significant effect on this picture," said von Minckwitz. "However, pathological response as a surrogate for outcome is only confirmed for chemotherapy. Long-term follow up, as well as results from adjuvant studies have to be awaited."

The researchers investigated whether adding bevacizumab to treatment with four cycles of epirubicin/cyclophosphomide, followed by four cycles of docetaxel improved the rate of pathological complete response, which was defined as no invasive or non-invasive residual cancer in the breast or nodes.

Between May 2007 and June 2010, 944 patients were assigned chemotherapy treatment with epirubicin/cyclophosphamide followed by docetaxel; 945 patients were assigned this treatment plus bevacizumab.

After the first four cycles, the researchers performed an interim assessment; 24 percent of patients treated without bevacizumab and 17 percent of patients treated with bevacizumab showed no response and were discontinued from treatment.

Interim safety data from the trial, published earlier this year, indicated that treatment with bevacizumab was feasible. Patients assigned bevacizumab experienced more leukopenia, infections, mucositis and hypertension, but less edema. This safety profile is no different from that reported in first-line metastatic trials or Phase II adjuvant trials of bevacizumab, according to von Minckwitz.

Full results on the histological response and surgical outcome will be reported during the symposium.

"The results will provide an important signal as to whether bevacizumab will be effective as an adjuvant treatment," said von Minckwitz.


Contact: Jeremy Moore
American Association for Cancer Research

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy ... , FDA has long asserted that design and manufacture of Laboratory Developed ... and do not meet the device regulations. , Come up short in an inspection ...
(Date:11/24/2015)... ... 2015 , ... United Benefit Advisors (UBA), the nation’s leading ... its newest Partner Firm. Based in Jefferson City, Missouri, their core philosophy is ... of whether that client is a business, a family, or an individual. ...
(Date:11/24/2015)... ... November 24, 2015 , ... With Thanksgiving right around the corner, holiday travel ... help protect your family and vehicle. , According to the National Highway Traffic Safety ... Amica is sharing the following safety tips from the NHTSA: , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Diego -based Imprimis Pharmaceuticals, Inc. (NASDAQ: ... development, production and dispensing of novel compounded pharmaceuticals.  ... segments including ophthalmology, urology, sinus and integrative medicine.  ... from four facilities located in California ... New Jersey and Pennsylvania.  For ...
(Date:11/24/2015)... Nov. 24, 2015  Freudenberg Medical has developed specialty tubing ... outside of medical facilities. Africa ... care is sparse. Nevertheless, prompt diagnosis is important to treat ... the virus. With the help of a portable mini-lab or ... to village in affected areas and perform rapid testing for ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology: